Scarica l'app Stockscreener
65.66
1.02%
0.66
Dopo l'orario di chiusura:
65.66
Precedente Chiudi:
$65.00
Aprire:
$64.9
Volume 24 ore:
2.86M
Relative Volume:
1.91
Capitalizzazione di mercato:
$12.51B
Reddito:
$2.75B
Utile/perdita netta:
$322.29M
Rapporto P/E:
85.42
EPS:
0.7687
Flusso di cassa netto:
$300.88M
1 W Prestazione:
-0.53%
1M Prestazione:
+4.96%
6M Prestazione:
-22.49%
1 anno Prestazione:
-29.14%
Intervallo 1D:
$64.07
$66.27
Intervallo di 1 settimana:
$63.93
$67.85
Portata 52W:
$61.15
$99.25
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
65.66 | 12.51B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Stifel Financial Corp Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Average Price Target from Brokerages - MarketBeat
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? - Yahoo Finance
BioMarin's SWOT analysis: rare disease leader's stock faces growth hurdles By Investing.com - Investing.com Canada
BioMarin's SWOT analysis: rare disease leader's stock faces growth hurdles - Investing.com
National Bank of Canada FI Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Tidal Investments LLC Raises Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Geode Capital Management LLC Acquires 60,692 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Teachers Retirement System of The State of Kentucky Sells 134,167 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Virtu Financial LLC Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time - The Eastern Progress Online
BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET - The Eastern Progress Online
The Latest Analyst Ratings For Biomarin Pharmaceutical - Benzinga
BioMarin's SWOT analysis: rare disease stock faces growth and competition - Investing.com
Major pharma-company invests €60m in new plant in vote of confidence for Cork - MSN
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Y Intercept Hong Kong Ltd Buys New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Neo Ivy Capital Management - MarketBeat
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Yahoo Finance
Fmr LLC Buys 36,877 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Canada Finance
Nomura Asset Management Co. Ltd. Acquires 110,683 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Two Sigma Advisers LP Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to add €60M lab to Irish manufacturing site in push to grow production capacity - FiercePharma
BioMarin's Rare Disease Portfolio and Strong Voxzogo Launch Support Narrow Moat Rating - Morningstar
BioMarin Pharmaceutical Inc announce €60m investment in Cork plant - Business Plus
BioMarin announces €60m Cork expansion - SiliconRepublic.com
BioMarin announces significant investment and expansion of Cork facility - Cork's 96FM
Worldquant Millennium Advisors LLC Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Centiva Capital LP Buys Shares of 7,511 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Jacobs Levy Equity Management Inc. Invests $3.66 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Participate in Three Upcoming Investor Conferences - The Eastern Progress Online
Interesting BMRN Put And Call Options For December 20th - Nasdaq
BioMarin Pharmaceutical (NASDAQ:BMRN) investors are sitting on a loss of 29% if they invested a year ago - Simply Wall St
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Motley Fool Wealth Management LLC - MarketBeat
Holocene Advisors LP Has $39.61 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
The Manufacturers Life Insurance Company Decreases Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Edgestream Partners L.P. Invests $2.01 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Lowers Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stake Lifted by Rockefeller Capital Management L.P. - MarketBeat
BNP Paribas Financial Markets Lowers Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
PDT Partners LLC Invests $2.32 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Erste Asset Management GmbH Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Bellevue Group AG Acquires 278,744 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Vestal Point Capital LP Buys New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Bridgewater Associates LP - MarketBeat
Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? - Yahoo Finance
FORA Capital LLC Acquires 16,926 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Dynamic Technology Lab Private Ltd Makes New $1.01 Million Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):